It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.